Profitability is supported by improved gross margins and operational efficiency: Aurobindo Pharma VCMD | Photo: Company website
Aurobindo Pharma on Saturday said its consolidated net profit rose 61 per cent year-on-year to Rs 919 crore in the first quarter ended June 2024, helped by strong sales across all markets.
The Hyderabad-based drugmaker had reported a net profit of Rs 571 crore in the April-June quarter of the last fiscal.
Revenue from operations rose to Rs 7,567 crore in the June quarter from Rs 6,851 crore in the same period a year ago, the pharmaceutical maker said in a statement.
“We are pleased with our continued strong performance this quarter, with significant revenue growth across all our business segments,” said Aurobindo Pharma Vice Chairman and Managing Director K Nithyananda Reddy.
Profitability was sustained by improved gross margins and operational efficiency, while we increased production from our recently commercialized plants, he added.
“We are confident in our ability to achieve our growth targets for FY25,” Reddy said.
(Only the headline and image of this report may have been reworked by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First published: August 10, 2024 | 20:25 IS
Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.